The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Open accessAbstract
The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years. We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (minimum inhibitory concentration 0.06 mug/ml). In mice, R207910 exceeded the bactericidal activities of isoniazid and rifampin by at least 1 log unit. Substitution of drugs included in the World Health Organization's first-line tuberculosis treatment regimen (rifampin, isoniazid, and pyrazinamide) with R207910 accelerated bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations. A single dose of R207910 inhibited mycobacterial growth for 1 week. Plasma levels associated with efficacy in mice were well tolerated in healthy human volunteers. Mutants selected in vitro suggest that the drug targets the proton pump of adenosine triphosphate (ATP) synthase.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 14 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 was extensively distributed to tissues, including lungs and spleen (Fig. 3A, table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These average concentrations were greater than that achieving optimal activity in established infection in mice.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Low MICs were also found for other mycobacterial species, including Mycobacterium bovis, Mycobacterium kansasii and Mycobacterium ulcerans, as well as species naturally resistant to many other anti-TB agents and involved in opportunistic infections, such as Mycobacterium avium complex (MAC), Mycobacterium abscessus, Mycobacterium fortuitum and Mycobacterium marinum (Table 1).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 25 mg/kg, the activity of R207910 was significantly better than at 12.5 mg/kg (P = 0.005).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The bactericidal activity obtained by the RHZ combination after 2 months of therapy was matched by the combinations JHZ and RJZ after just 1 month of therapy.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, at 12.5 and 25 mg/kg, R207910 was significantly more active (P = 0.005) than 25 mg/kg isoniazid, a drug known for its strong, early bactericidal activity (Fig. 4A).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, the susceptibility of R207910-resistant M. tuberculosis strains remained unchanged to other anti-TB agents, including isoniazid, rifampin, streptomycin, amikacin, ethambutol and moxifloxacin.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“To date, 20 molecules of the DARQ series have a minimum inhibitory concentration (MIC) below 0.5 µg/ml against M. tuberculosis H37Rv.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data from a multiple-ascending-dose study have shown an increase (approximately by a factor of two) in AUC 0-24h from Day 1 to Day 14 of once-daily dosing at 50, 150 and 400 mg R207910, without substantial variation between subjects.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Plasma levels associated with efficacy in mice are well tolerated in healthy human volunteers.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclear
- Probably not a substantial claim. 3
- It may state two separate claims as one. 40
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The most active compound of the class, R207910, is a pure enantiomer with two chiral centers.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“No accumulation of R207910 was observed after five daily oral doses, indicating that slow redistribution from tissues contributed to the relatively long half-lives in plasma.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the second study, the good tolerability was maintained; only one subject withdrew from the study, because of a urinary tract infection (unrelated to R207910) after seven doses at 150 mg/day.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:plain· not yet calibratedSingle caseTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When added to the first-line triple TB therapy combination RHZ, 25 mg/kg R207910 (J) increased the drop in bacterial load in the lungs by 2 log 10 after 1 month of therapy compared with standard RHZ treatment regimen, and a further 1 log 10 drop after 2 months.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Maximum plasma concentrations (C max ) of 0.40-0.54µg/ml with a single 6.25 mg/kg/dose were achieved within 1 hour and 1.1-1.3µg/ml with a 25 mg/kg/dose within 2-4 hours.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The majority of adverse events reported (supporting online text), were considered possibly related to the study medication-placebo (seven of 18 subjects) or R207910 (20 of 36 subjects).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The AUC showed a better correlation with the dose than C max , reflecting limitations in rate of absorption at higher dosing regimens, as confirmed in a single-dose pharmacokinetic study comparing C max and AUC after 6.25, 25 and 100 mg/kg.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This anti-mycobacterial-specific spectrum differs from that of isoniazid, which has very poor activity against MAC.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In studies using oral treatment of R207910 for 5 days per week for 4 weeks, starting the day after inoculation, the minimal dose of R207910 that prevented mortality in nonestablished infection was 1.5 mg/kg, and the minimal effective dose (MED) preventing gross lung lesions was 6.5 mg/kg.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Exposure of M. tuberculosis in log-phase growth to concentrations of R207910 at 10-fold MIC resulted in a 3 log 10 reduction in bacterial counts after 12 days, indicating that R207910 has bactericidal activity in vitro (table S2).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Complementation studies have verified that the mutant atpE gene is responsible for resistance to R207910, implying that the atpE gene product is the target of R207910 in mycobacteria.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The range of MICs for the international reference strain M. tuberculosis H37Rv and six fully antibiotic susceptible isolates was 0.03-0.120µg/ml (Table 1), versus 0.500 µg/ml for rifampin and 0.120 µg/ml for isoniazid (results not shown).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 30 isolates of MDR-TB tested were susceptible to 0.100 µg/ml of R207910, and 17 (57%) were susceptible to 0.010 µg/ml of R207910 (Table 2).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Pharmacokinetic results from the single-ascending-dose study suggested that R207910 is well absorbed after single oral administration, and the peak concentration was reached at 5 hours (median value) post-dose.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 had much higher MICs for Corynebacterium and Helicobacter pylori (MIC 4.0 µg/ml), and especially for other organisms such as Gram-positive Nocardia, Streptococcus pneumoniae, Staphylococcus aureus and Enterococcus faecalis, or Gram-negative Escherichia coli and Haemophilus influenzae (table S1).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Half-lives ranged from 43.7 to 64 hours in plasma and 28.1 to 92 hours in tissues (table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of drugs included in the World Health Organization's firstline tuberculosis treatment regimen (rifampin, isoniazid and pyrazinamide) with R207910 accelerates bactericidal activity, leading to complete culture conversion after 2 months of treatment in some combinations.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The DARQ R207910 is a member of a new chemical class of anti-mycobacterial agents and has an MIC equal to or lower than that of reference compounds.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A single dose of 50 mg/kg R207910 in the non-established infection murine model of TB infection resulted in a bacteriostatic effect (0.5 log 10 drop in bacterial count in the lungs), which lasted for 8 days-a similar effect to that of rifapentine (10 mg/kg) (Fig. 3B).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In established infection (treatment beginning 12-14 days after inoculation when bacterial load was 5.94 log 10 CFU), 25 mg/kg R207910 as monotherapy was at least as active as the triple combination therapy (rifampin [R] + isoniazid [H] + pyrazinamide [Z]), and more active than rifampin alone (Fig. 4B).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We identified a diarylquinoline, R207910, that potently inhibits both drug-sensitive and drug-resistant Mycobacterium tuberculosis in vitro (MIC 0.06 µg/ml).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean AUC 0-24h values were 7.91, 24 and 52 µg/hour/ml at steady state, corresponding to average concentrations of 0.33, 1.0 and 2.2 µg/ml across a dosing interval, with 50, 150 and 400 mg/day, respectively.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pharmacokinetics of R207910 were linear up to the highest dose tested (700 mg); both C max and AUC increased proportionally with the administered dose.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The two point mutations identified (D32V for M. smegmatis and A63P for M. tuberculosis) are both in the membrane-spanning domain region of the protein.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Areas under the concentration-time curve (AUCs) ranged from 5.0 to 5.9 µg/hour/ml with a 6.25 mg/kg/dose and 18.5 to 19.4 µg/hour/ml with a 25 mg/kg/dose (table S4).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“From selection experiments, the proportion of resistant mutants that emerged was 5 x 10 -7 and 2 x 10 -8 at four-fold MIC, and 5 x 10 -8 and 1 x 10 -8 at eight-fold MIC for M. tuberculosis and M. smegmatis, respectively (8).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
What the sources say
- Not matchedcites [8] 8. Details of materials and methods and supporting online text are available as supporting material on Science Online.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Substitution of each of the three first-line drugs with R207910 resulted in a dramatic increase in potency, leading to complete culture conversion of the lungs in some animals after only 2 months of treatment.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“R207910 has potent early bactericidal activity in the nonestablished murine TB model, matching or exceeding that of isoniazid (Fig. 4A), which is consistent with in vitro observations pointing to a bactericidal activity.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, the bactericidal potency seen upon administration of a single dose of 100 mg/kg R207910 in vivo was similar to the effect seen upon continuous exposure of cultures to 0.6 µg/ml (or 10-fold the median MIC of the H37Rv strain) in vitro, giving a first indication of the pharmacodynamics of R207910.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the minimal bactericidal dose was very close to the MED, a finding confirming timedependent, rather than concentration-dependent, activity of R207910 in vitro.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Pharmacodynamic studies in mice.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data suggest that maintaining average plasma levels of 0.3 µg/ml/day across a dosing interval, which is achieved with a 100 mg/kg/week dose, is necessary to achieve optimal effect of monotherapy in mice infected with strain H37Rv.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The killing effect was not increased by higher concentrations of the compound, suggesting the killing was time-dependent rather than concentration-dependent.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Although current first-line anti-TB drug regimens can achieve more than 99% efficacy, this is often reduced because of drug resistance (5).”
What the sources say
- Not matchedcites [5] 5. R. J. O'Brien, P. P. Nunn, Am. J. Respir. Crit. Care Med. 163, 1055 (2001).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Not matched
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Structurally and mechanistically, DARQs are very different from both fluoroquinolones (including methoxyquinolones) and other quinoline classes, including mefloquine and its analogs 4-methylquinolines and 4quinolylhydrazones (9-13).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
What the sources say
- Not matchedcites [9] 9. R. Jain, B. Vaitilingam, A. Nayyar, P. B. Palde, Bioorg. Med. Chem. Lett. 13, 1051 (2003).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [10] 10. C. M. Kunin, W. Y. Ellis, Antimicrob. Agents Chemother. 44, 848 (2000).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [11] 11. M. R. Barbachyn, S. J. Brickner, Patent (International Publication Number: WO 93/09103, International Publication Date: 13 May, 1993, International Application Number: PCT/US92/08267, International Filing Date: 1992).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [12] 12. L. Savini, L. Chiasserini, A. Gaeta, C. Pellerano, Bioorg. Med. Chem. 10, 2193 (2002). / www.sciencexpress.org /9 December 2004 / Page 4/ 10.1126/science.1106753
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [13] 13. S. Vangapandu, M. Jain, R. Jain, S. Kaur, P. P. Singh, Bioorg. Med. Chem. 12, 2501 (2004).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The long half-lives and consequently prolonged exposure are important factors determining the duration of activity in vivo and provide a rationale for less frequent dosing regimens.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Chemistry and in vitro anti-mycobacterial activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A comparison of the sequences of ATP synthases of different bacteria and of eukaryotic ATP synthase provides a rationale for the specificity of the antibacterial spectrum and, to a lesser extent, the safety profile of R207910.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, the distinct target of R207910 means that there is no crossresistance with existing anti-TB drugs, and our studies verified it is as effective against MDR strains as it is against fully antibiotic-susceptible strains.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim could be matched to a paper in Crossref, so there is nothing to check it against.
In the paper
“Inhibition of ATP synthase function may lead to ATP depletion and imbalance in pH homeostasis, both contributing to decreased survival (15,16).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
What the sources say
- Not matchedcites [15] 15. M. Rao, T. L. Streur, F. E. Aldwell, G. M. Cook, Microbiology 147, 1017 (2001).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not matchedcites [16] 16. G. Deckers-Hebestreit, K. Altendorf, Annu. Rev. Microbiol. 50, 791 (1996).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These are all attributes that are valuable for treatment of chronic infections and they may also be important for the development of simpler dosing regimens.”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“The extent of bacterial load, the most effective drug combinations and treatment duration needed for sterilization are all similar in mice and humans (17).”
§ A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis > Safety and tolerability in humans.
What the sources say
- Not matchedcites [17] 17. E. L. Nuermberger et al., Am. J. Respir. Crit. Care Med. 169, 421 (2004).
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Not matched
The paper relies on this without support.
No tuberculosis-specific drugs have been discovered in 40 years.
“Tuberculosis has been increasing significantly on a worldwide basis over the past decade, but no tuberculosisspecific drugs have been discovered in 40 years.”
The paper relies on this without support.
The murine TB model is predictive of human TB treatment outcomes.
“The extent of bacterial load, the most effective drug combinations and treatment duration needed for sterilization are all similar in mice and humans (17).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TMC207 is bactericidal towards most species of mycobacteria (109), but is only bacteriostatic against M. avium (118) and M. smegmatis (Berney and Cook, unpublished data).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When mycobacterial cells (growing or non-growing) are treated with TMC207, time-dependent (not dose-dependent) killing is observed (109).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“M. smegmatis was used for the initial compound screening that identified diarylquinoline (later named Bedaquiline) as a specific inhibitor of mycobacterial ATP synthase in 2005, which ended a 40-year dearth in anti-TB drug discovery (147).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [147]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, Bedaquiline, the first new TB drug in 40 years, was discovered through an M. smegmatis screen.”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [147]
Citations
Cites
Amino acid substitution matrices from protein blocks.
Henikoff, S., & Henikoff, J. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10915 · Cited by 6,218
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Comparing the Means of Several Groups
Godfrey, K. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512053132305 · Cited by 740
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Nuermberger, E. L., Yoshimatsu, T., Tyagi, S. K., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200310-1380oc · Cited by 315
Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis
Siddiqi, S. H., Libonati, J. P., & Middlebrook, G. (1981) · Journal of Clinical Microbiology · doi:10.1128/jcm.13.5.908-912.1981 · Cited by 242
The Need for New Drugs against Tuberculosis
O'BRIEN, R. J., & NUNN, P. P. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2007122 · Cited by 221
THE F0F1-TYPE ATP SYNTHASES OF BACTERIA: Structure and Function of the F0 Complex
Deckers-Hebestreit, G., & Altendorf, K. (1996) · Annual Review of Microbiology · doi:10.1146/annurev.micro.50.1.791 · Cited by 195
Intracellular pH regulation by Mycobacterium smegmatis and Mycobacterium bovis BCG
Rao, M., Streur, T. L., Aldwell, F. E., & Cook, G. M. (2001) · Microbiology · doi:10.1099/00221287-147-4-1017 · Cited by 148
Synthesis and anti-tubercular evaluation of 4-quinolylhydrazones
Savini, L., Chiasserini, L., Gaeta, A., & Pellerano, C. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00071-8 · Cited by 134
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 2,159
Bioluminescence for Assessing Drug Potency against Nonreplicating Mycobacterium tuberculosis
Vocat, A., Hartkoorn, R. C., Lechartier, B., Zhang, M., Dhar, N., Cole, S. T., & Sala, C. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00528-15 · Cited by 38
“Experimental drugs were kindly provided by Sanofi-Aventis (rifapentine [RFP]), Tibotec (bedaquiline [BDQ]), V. Makarov (benzothiazinone [BTZ043]), M. Jackson (adamantyl urea [AU1235]), H. Boshoff (SQ109), and C. E. Barry III (sutezolid [STZ]).”
InfluentialRoles of the two type II NADH dehydrogenases in the survival of Mycobacterium tuberculosis in vitro
Awasthy, D., Ambady, A., Narayana, A., Morayya, S., & Sharma, U. K. (2014) · Gene · doi:10.1016/j.gene.2014.08.024 · Cited by 37
“However, the recently FDA approved anti-TB drug TMC-207 (Bedaquiline) works by inhibiting ATP synthase (Andries et al., 2005; Segala et al., 2012).”
BackgroundHarrison, G. A., Bridwell, A. E. M., Singh, M., Jayaraman, K., Weiss, L. A., Kinsella, R. L., Aneke, J. S., Flentie, K., Schene, M. E., Gaggioli, M. R., et al. (2019) · mSphere · doi:10.1128/msphere.00606-19 · Cited by 37
“In 2012, the diarylquinoline compound bedaquiline (Sirturo), which inhibits the mycobacterial ATP synthase (2), was approved to treat MDR-TB patients (3).”
BackgroundBedaquiline-Resistant Tuberculosis Associated with Rv0678 Mutations
Omar, S. V., Ismail, F., Ndjeka, N., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2103049 · Cited by 36
Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent
Huang, Z., Luo, W., Xu, D., et al. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128824 · Cited by 36
New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
Diaz, J. M. A., Abulfathi, A. A., Brake, L. H. M. T., van Ingen, J., Kuipers, S., Magis-Escurra, C., Raaijmakers, J., Svensson, E. M., & Boeree, M. J. (2022) · Respiration · doi:10.1159/000528274 · Cited by 38
Bedaquiline: A Novel Antitubercular Agent for the Treatment of Multidrug- Resistant Tuberculosis
Yadav, S. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/19052.8286 · Cited by 36
“tuberculosis to BDQ is unchanged in the presence of resistance to other antitubercular drugs, including Isoniazid, Rifampicin, Ethambutol, Streptomycin, and Moxifloxacin [14].”
BackgroundInfluentialOld and new drugs for the treatment of tuberculosis in children
Donald, P. R., & Schaaf, H. S. (2007) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2007.04.001 · Cited by 36
Structure of mycobacterial respiratory complex I
Liang, Y., Plourde, A., Bueler, S. A., Liu, J., Brzezinski, P., Vahidi, S., & Rubinstein, J. L. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214949120 · Cited by 31
“The discovery and subsequent approval of the tuberculosis drug bedaquiline, which inhibits mycobacterial ATP synthase, identified oxidative phosphorylation as a valuable target for new antibiotics for mycobacteria (2, 3).”
Walter, N. D., Ernest, J. P., Dide-Agossou, C., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00284-23 · Cited by 35
Detection and treatment of subclinical tuberculosis
Robertson, B. D., Altmann, D. M., Barry, C. E., Bishai, B., Cole, S. T., Dick, T., Duncan, K., Dye, C., Ehrt, S., Esmail, H., et al. (2012) · Tuberculosis · doi:10.1016/j.tube.2012.06.004 · Cited by 35
Lü, P., Villellas, C., Koul, A., Andries, K., Lill, H., & Bald, D. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.74 · Cited by 33
Self-citationMycobacterium Tuberculosis Evolutionary Pathogenesis and its Putative Impact on Drug Development
Chevalier, F. L., Cascioferro, A., Majlessi, L., Herrmann, J., & Brosch, R. (2014) · Future Microbiology · doi:10.2217/fmb.14.70 · Cited by 40
“tuberculosis.[39] The activity of TMC207 on multidrug-resistant M.”
BackgroundLipids in Insect Oocytes: From the Storage Pathways to Their Multiple Functions
Fruttero, L. L., Leyria, J., & Canavoso, L. E. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-60855-6_18 · Cited by 35
Evolution of Phenotypic and Molecular Drug Susceptibility Testing
Cirillo, D. M., Miotto, P., & Tortoli, E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-64371-7_12 · Cited by 36
Molecular mechanistic insights into uncoupling of ion transport from ATP synthesis
Nath, S. (2018) · Biophysical Chemistry · doi:10.1016/j.bpc.2018.08.006 · Cited by 35
Beteck, R. M., Seldon, R., Jordaan, A., et al. (2019) · MedChemComm · doi:10.1039/c8md00480c · Cited by 35
2-aminoimidazoles collapse mycobacterial proton motive force and block the electron transport chain
Jeon, A. B., Ackart, D. F., Li, W., Jackson, M., Melander, R. J., Melander, C., Abramovitch, R. B., Chicco, A. J., Basaraba, R. J., & Obregón‐Henao, A. (2019) · Scientific Reports · doi:10.1038/s41598-018-38064-7 · Cited by 35
Inhaled Antibiotics for Mycobacterial Lung Disease
Banaschewski, B. J. H., & Hofmann, T. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11070352 · Cited by 35
“Similar to streptomycin-resistant TB in the 1950s and 1960s, the potential benefits of inhaled therapeutics has recently been outshined by the discovery of new antibiotics, such as bedaquiline [146], delamanid [159], and pretomanid [160].”
BackgroundSaw, W. G., Wu, M.-L., Ragunathan, P., Biuković, G., Lau, A., Shin, J. S., Harikishore, A., Cheung, C., Hards, K., Sarathy, J. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53107-3 · Cited by 35
Primary Bedaquiline Resistance Among Cases of Drug-Resistant Tuberculosis in Taiwan
Wu, S.-H., Chan, H.-H., Hsiao, H.-C., & Jou, R. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.754249 · Cited by 40
“Additionally, BDQ exhibits no crossresistance to current first-line and second-line anti-TB drugs except clofazimine (CFZ; Andries et al., 2005).”
BackgroundInfluentialAbuhammad, A., Lowe, E. D., McDonough, M. A., Stewart, P. D. S., Kolek, S., Sim, E., & Garman, E. F. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913015126 · Cited by 35
“Several completely novel drugs are now in clinical development, foremost of which is the ATPase inhibitor bedaquiline (TMC-207; Cole & Riccardi, 2011; Andries et al., 2005; Grosset et al., 2012).”
BackgroundMethodCabrera, L. V., Brown‐Elliott, B. A., Wallace, R. J., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00763-06 · Cited by 35
“These include new quinolones, a recently described ATPase inhibitor (R207910), and ethambutol derivatives such as SQ109 (1, 10).”
BackgroundGELBER, R. H., Andries, K., Paredes, R. M. D., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00722-09 · Cited by 35
“In murine tuberculosis, daily administration of R207910 alone exceeds the bactericidal activity of the standard WHO regimen (isoniazid, rifampin [rifampicin], and pyrazinamide) (1).”
BackgroundInfluentialSelf-citationEngohang‐Ndong, J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.724397 · Cited by 34
“smegmatis resistant to TMC207 suggest that the drug targets the proton pump that is coupled with adenosine triphosphate (ATP) synthase [27].”
BackgroundKwon, Y. S., Jeong, B., & Koh, W. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000045 · Cited by 34
“tuberculosis and potent bactericidal activity in a murine model exceeding that of isoniazid and rifampin [36].”
BackgroundInfluentialGurcha, S. S., Usha, V., Cox, J. A. G., Fütterer, K., Abrahams, K. A., Bhatt, A., Alderwick, L. J., Reynolds, R. C., Loman, N. J., Nataraj, V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113568 · Cited by 33
Casoni, G., Myers, E. L., & Aggarwal, V. K. (2016) · Synthesis · doi:10.1055/s-0035-1562447 · Cited by 34
Next Generation Genome Sequencing
Janitz, M. (2008) · Wiley eBooks · doi:10.1002/9783527625130 · Cited by 35
Cox, J. A. G., Mugumbate, G., Peral, L. V.-G. D., Jankute, M., Abrahams, K. A., Jervis, P. J., Jackenkroll, S., Pérez, A., Alemparte, C., Esquivias, J., et al. (2016) · Scientific Reports · doi:10.1038/srep38986 · Cited by 33
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis
Nguyen, P. C., Delorme, V., Bénarouche, A., Guy, A., Landry, V., Audebert, S., Pophillat, M., Camoin, L., Crauste, C., Galano, J., et al. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.08.025 · Cited by 34
Guo, Q., Bi, J., Lin, Q., Ye, T., Wang, Z., Wang, Z., Liu, L., & Zhang, G. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.807095 · Cited by 35
Balcaen, L. I. L., Samber, B. D., Wolf, K. D., et al. (2007) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-007-1303-2 · Cited by 34
Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery
Walsh, C. T., & Fischbach, M. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813405106 · Cited by 33
“tuberculosis ATP synthase (6) is in late-stage clinical evaluation, and semisynthetic derivatives of the ADEP family of natural products allosterically activate ATP-dependent chambered proteases (7).”
BackgroundTriazaspirodimethoxybenzoyls as Selective Inhibitors of Mycobacterial Lipoamide Dehydrogenase,
Bryk, R., Arango, N., Venugopal, A., et al. (2010) · Biochemistry · doi:10.1021/bi9016186 · Cited by 34
“A diarylquinoline that inhibits ATP synthase was the first agent targeting bacterial energy production to enter clinical trials (8,9).”
BackgroundMechanism of Action of 5-Nitrothiophenes against Mycobacterium tuberculosis
Hartkoorn, R. C., Riabova, O., Chiarelli, L. R., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02693-13 · Cited by 34
Towards new tuberculosis drugs
Cole, S. T., & Alzari, P. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351321 · Cited by 34
Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis
Narendran, G., Padmapriyadarsini, C., Swaminathan, S., et al. (2016) · AIDS Research and Therapy · doi:10.1186/s12981-016-0118-7 · Cited by 34
“CYP3A4 is the major cytochrome isoenzyme that metabolizes bedaquiline to M2, that is mainly removed in the stools, with only 1–4 % excreted in urine [107].”
BackgroundLi, J., Zhang, J., Yang, H., & Jiang, G. (2017) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b03064 · Cited by 34
López, B., de Oliveira, R. S., Pinhata, J. M. W., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky414 · Cited by 34
Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis
Sheikh, B. A., Bhat, B. A., Mehraj, U., Mir, W. R., Hamadani, S., & Mir, M. A. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021666200628021702 · Cited by 34
The Mycobacterium tuberculosis genome at 25 years: lessons and lingering questions
Koleske, B. N., Jacobs, W. R., & Bishai, W. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci173156 · Cited by 38
13[C]-Urea Breath Test as a Novel Point-of-Care Biomarker for Tuberculosis Treatment and Diagnosis
Jassal, M. S., Nedeltchev, G. G., Lee, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012451 · Cited by 33
“After a long hiatus in the development of new drugs for the treatment of tuberculosis (TB), exciting compounds such as TMC207/ R207910, PA824 and OPC6768 are coming out of preclinical stages and entering into clinical trials, with the promise of other new compounds to follow [1–3].”
BackgroundTB Mobile: a mobile app for anti-tuberculosis molecules with known targets
Ekins, S., Clark, A. M., & Sarker, M. (2013) · Journal of Cheminformatics · doi:10.1186/1758-2946-5-13 · Cited by 36
“; licensee Chemistry Centra Commons Attribution License (http://creative reproduction in any medium, provided the or targets have been addressed with approved drugs and recent testing has targeted additional proteins but this has yet to result in a drug besides bedaquiline for multidrug resistant TB [5,6].”
BackgroundClark, A. M., Sarker, M., & Ekins, S. (2014) · Journal of Cheminformatics · doi:10.1186/s13321-014-0038-2 · Cited by 35
“They should also be sorted and not contain duplicates, e.g. if atom 10 has neighbors 5, 7 and 12, the atom list for the proposed fingerprint at iteration 1 would be [5,7,10,12].”
BackgroundMethodResultPredictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis
Djaout, K., Singh, V., Boum, Y., Katawera, V., Becker, H. F., Bush, N. G., Hearnshaw, S. J., Pritchard, J. E., Bourbon, P., Madrid, P. B., et al. (2016) · Scientific Reports · doi:10.1038/srep27792 · Cited by 36
Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India
Udwadia, Z. F., Ganatra, S., & Mullerpattan, J. (2017) · European Respiratory Journal · doi:10.1183/13993003.01699-2016 · Cited by 33
Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system
Pamreddy, A., Baijnath, S., Naicker, T., Ntshangase, S., Mdanda, S., Lubanyana, H., Kruger, H. G., & Govender, T. (2018) · RSC Advances · doi:10.1039/c8ra00984h · Cited by 34
Ismail, N. A., Omar, S. V., Ismail, N. A., et al. (2018) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2018.08.011 · Cited by 33
Makane, V. B., Krishna, V. S., Krishna, E. V., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.002 · Cited by 33
Handling the Hurdles on the Way to Anti-tuberculosis Drug Development
Dalberto, P. F., de Souza, E. V., Abbadi, B. L., Neves, C. E., Rambo, R. S., Ramos, A. S., Macchi, F. S., Machado, P., Bizarro, C. V., & Basso, L. A. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.586294 · Cited by 33
“Bedaquiline has a mechanism of action that differs from those currently used drugs: it inhibits mycobacterial ATP synthase and depletes cellular energy stores (Andries et al., 2005).”
BackgroundBroussy, S., Bernardes‐Génisson, V., Quémard, A., Meunier, B., & Bernadou, J. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo051901z · Cited by 33
Nakano, C., Ootsuka, T., TAKAYAMA, K., et al. (2011) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.100570 · Cited by 33
Li, N., Wang, F., Niu, S., et al. (2009) · BMC Microbiology · doi:10.1186/1471-2180-9-129 · Cited by 33
“A case in point is the discovery of a leadcompound named diarylquinoline against Mycobacterium tuberculosis [26].”
BackgroundHealan, A. M., Griffiss, J. M., Proskin, H. M., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00855-17 · Cited by 33
“Bedaquiline has a reported elimination half life of approximately 5 months (2, 9).”
BackgroundSarathy, J. P., Ragunathan, P., Cooper, C. B., Upton, A. M., Grüber, G., & Dick, T. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01540-19 · Cited by 32
“terium tuberculosis F1FO-ATP synthase through targeting of both the c (1, 4) and the (5–7) subunits.”
BackgroundRieske head domain dynamics and indazole-derivative inhibition of Candida albicans complex III
Di Trani, J. M., Liu, Z., Whitesell, L., Brzezinski, P., Cowen, L. E., & Rubinstein, J. L. (2022) · Structure · doi:10.1016/j.str.2021.08.006 · Cited by 32
Molecular Mechanisms of MmpL3 Function and Inhibition
Williams, J. T., & Abramovitch, R. B. (2023) · Microbial Drug Resistance · doi:10.1089/mdr.2021.0424 · Cited by 31
Amorphous Drug Nanoparticles for Inhalation Therapy of Multidrug-Resistant Tuberculosis
Rudolph, D., Redinger, N., Schwarz, K., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c01664 · Cited by 32
Negi, A., Perveen, S., Gupta, R., Singh, P. P., & Sharma, R. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01892 · Cited by 34
Tuberculosis: An Update for the Clinician
Janssen, S., Murphy, M., Upton, C. M., Allwood, B., & Diacon, A. H. (2025) · Respirology · doi:10.1111/resp.14887 · Cited by 35
Identifying co-targets to fight drug resistance based on a random walk model
Chen, L., Yeh, H., Yeh, C.-Y., Arias, C. R., & Soo, V. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-5 · Cited by 30
“46 In Vitro essential ATP synthase A chain [55,67]”
BackgroundMicrobial transformation of azaarenes and potential uses in pharmaceutical synthesis
Parshikov, I. A., Netrusov, A. I., & Sutherland, J. B. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4220-z · Cited by 32
Abuhammad, A., Fullam, E., Lowe, E. D., Staunton, D., Kawamura, A., Westwood, I. M., Bhakta, S., Garner, A. C., Wilson, D., Seden, P. T., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052790 · Cited by 32
“New compounds with a variety of mechanisms of action are being developed and are in the preclinical and clinical phase [29,30].”
BackgroundIzmer, A. V., Gholap, D., Houwer, K. D., et al. (2012) · Journal of Analytical Atomic Spectrometry · doi:10.1039/c2ja10343e · Cited by 32
Wlodarchak, N., Teachout, N., Beczkiewicz, J., Procknow, R. R., Schaenzer, A. J., Satyshur, K. A., Pavelka, M. S., Zuercher, W. J., Drewry, D. H., Sauer, J., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00905 · Cited by 32
Converse, P. J., Almeida, D. V., Tyagi, S. K., Xu, J., & Nuermberger, E. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00426-19 · Cited by 32
“BDQ targets ATP synthase (24), resulting in the inhibition of ATP production.”
BackgroundMolecule Property Analyses of Active Compounds for Mycobacterium tuberculosis
Makarov, V., Salina, E. G., Reynolds, R. C., Zin, P. P. K., & Ekins, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02075 · Cited by 35
Nizi, M. G., Desantis, J., Nakatani, Y., Massari, S., Mazzarella, M. A., Shetye, G. S., Sabatini, S., Barreca, M. L., Manfroni, G., Felicetti, T., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112420 · Cited by 31
“The entire mycobacterial respiratory chain is an important source of antimycobacterial drug targets,[25,26] as demonstrated by the FDA‐approval of bedaquiline (BDQ) that targets F1F0-ATP synthase.[27] Various chemical compounds have been identified as NDH-2 inhibitors although none have”
BackgroundSmall organic molecules targeting the energy metabolism of Mycobacterium tuberculosis
Urban, M., Šlachtová, V., & Brulíková, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113139 · Cited by 34
Tuberculosis: The Past, the Present and the Future
Koegelenberg, C. F. N., Schoch, O. D., & Lange, C. G. (2021) · Respiration · doi:10.1159/000516509 · Cited by 33
Ji, X., Huang, H., Li, Y., et al. (2012) · Angewandte Chemie · doi:10.1002/ange.201202412 · Cited by 32
Tuberculosis: The success tale of less explored dormant Mycobacterium tuberculosis
Verma, A., Ghoshal, A., Dwivedi, V. P., & Bhaskar, A. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1079569 · Cited by 36
“If these drugs cannot be used, then other drugs like Ethambutol, Delamanid, Pyrazinamide, Meropenam, Amikacin, Ethionamide, paminosalicylic acid are added to complete the regimen (Andries et al., 2005).”
BackgroundMogi, T., & Kita, K. (2009) · Mitochondrion · doi:10.1016/j.mito.2009.08.004 · Cited by 32
New drugs and regimens for tuberculosis
Chang, K. C., Nuermberger, E. L., Sotgiu, G., et al. (2018) · Respirology · doi:10.1111/resp.13345 · Cited by 32
Desensitization Therapy for Allergic Reactions to Antituberculous Drugs
Kobashi, Y., Abe, T., Shigeto, E., et al. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.3590 · Cited by 32
Adolph, C., McNeil, M. B., & Cook, G. M. (2022) · mBio · doi:10.1128/mbio.01672-22 · Cited by 32
“Several inhibitors of the mycobacterial respiratory chain have now 65 been identified including the only three new TB drugs to be approved in the last 50 years; 66 bedaquiline (BDQ), which inhibits the mycobacterial F1Fo ATP synthase (15-17) and 67”
BackgroundSnobre, J., Villellas, M. C., Coeck, N., Mulders, W., Tzfadia, O., de Jong, B. C., Andries, K., & Rigouts, L. (2023) · Scientific Reports · doi:10.1038/s41598-023-36955-y · Cited by 34
Self-citationMycobacterial Nicotinate Mononucleotide Adenylyltransferase
Rodionova, I. A., Zuccola, H. J., Sorci, L., Aleshin, A. E., Kazanov, M. D., Ma, C.-T., Sergienko, E. A., Rubin, E. J., Locher, C. P., & Osterman, A. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.628016 · Cited by 30
“The recent approval of the ATP biogenesis inhibitor bedaquiline for the treatment of drug-resistant tuberculosis is an important milestone in this direction (6, 7).”
BackgroundPatel, S. R., Gangwal, R. P., Sangamwar, A. T., & Jain, R. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.02.034 · Cited by 31
Massire, C., Ivy, C. A., Lovari, R., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01578-10 · Cited by 31
“A prime example is the atpE primer pair, which amplifies a region associated with mutations that provide resistance to diarylquinoline (2, 31) but is also useful for NTM characterization.”
BackgroundReactive dirty fragments: implications for tuberculosis drug discovery
Gopal, P., & Dick, T. (2014) · Current Opinion in Microbiology · doi:10.1016/j.mib.2014.06.015 · Cited by 33
“A few years ago, after a decade of biochemical high throughput screening against genetically validated targets, the antimycobacterial discovery field largely moved back to phenotypic whole cell screens to identify compounds with antimicrobial activity first, then deconvolute the target for lead optimization [7].”
BackgroundSingh, V., Dhar, N., Pató, J., Kolly, G. S., Korduláková, J., Forbak, M., Evans, J. C., Székely, R., Rybniker, J., Palčeková, Z., et al. (2017) · Molecular Microbiology · doi:10.1111/mmi.13535 · Cited by 25
“, 2015)) and AtpE (the target of bedaquiline (Andries et al., 2005)).”
BackgroundRao, N. S., Shaik, A. B., Routhu, S. R., et al. (2017) · ChemistrySelect · doi:10.1002/slct.201602022 · Cited by 31
Guinn, K. M., & Rubin, E. J. (2017) · mBio · doi:10.1128/mbio.01910-17 · Cited by 30
“These drugs include antibiotics that are used in other infections, such as linezolid (89), and new classes of drugs, such as bedaquiline (90) and delamanid (91), with novel mechanisms of action.”
BackgroundMucosal Therapy of Multi-Drug Resistant Tuberculosis With IgA and Interferon-γ
Tran, A. C., Diogo, G. R., Paul, M. J., Copland, A., Hart, P. J., Mehta, N., Irvine, E. B., Mussá, T., Drake, P. M. W., Iványi, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582833 · Cited by 32
“While the new drugs such as bedaquiline (17) and delamanid (18) hold promise, treatment of MDR-TB still remains difficult, with long duration, significant drug toxicity and comparatively”
BackgroundPecora, F., Canto, G. D., Veronese, P., & Esposito, S. (2021) · Microorganisms · doi:10.3390/microorganisms9051074 · Cited by 31
New Approaches to Filling the Gap in Tuberculosis Drug Discovery
Casenghi, M., Cole, S. T., & Nathan, C. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040293 · Cited by 31
Vashisht, R., Bhat, A. G., kushwaha, S., Bhardwaj, A., & Brahmachari, S. K. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0263-5 · Cited by 31
“Off these operons, the sugA ~ C has been suggested to involved in carbohydrate transport to maintain Mtb virulence in the context of host-pathogen interaction [58], atpA ~ H codes of ATP-Synthase, which has been proposed as drug target earlier [59].”
BackgroundHoshino, T., Nakano, C., Ootsuka, T., et al. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00884b · Cited by 31
Targeting the Histidine Pathway in Mycobacterium tuberculosis
Lunardi, J., Nunes, J., Bizarro, C. V., Basso, L. A., Santos, D. S., & Machado, P. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660203 · Cited by 32
“Recently, studies with diarylquinolines (DARQs), a new class of potent inhibitors of Mtb ATP synthase [14-18], led the U.”
BackgroundWu, X., Li, F., Wang, X., Li, C., Meng, Q., Wang, C., Huang, J., Chen, S., & Zhu, Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.136 · Cited by 31
Kazemi, M., Akbari, A., Soleimanpour, S., et al. (2019) · Journal of Cluster Science · doi:10.1007/s10876-019-01537-4 · Cited by 31
Calcagno, A., Coppola, N., Sarmati, L., Tadolini, M., Parrella, R., Matteelli, A., Riccardi, N., Trezzi, M., Biagio, A. D., Pirriatore, V., et al. (2024) · Infection · doi:10.1007/s15010-024-02183-3 · Cited by 31
Next generation sequencing technologies
Jarvie, T. P. (2005) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2005.08.003 · Cited by 30
A novel quinoline derivative that inhibits mycobacterial FtsZ
Mathew, B., Ross, L. J., & Reynolds, R. C. (2013) · Tuberculosis · doi:10.1016/j.tube.2013.04.002 · Cited by 30
Fruttero, L. L., Demartini, D. R., Rubiolo, E. R., et al. (2014) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2014.06.002 · Cited by 30
Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis
Lu, X., Tang, J., Liu, Z., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.11.003 · Cited by 30
Svensson, E. M., du Bois, J., Kitshoff, R., et al. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13696 · Cited by 30
Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors
Patel, H., Jadhav, H., Ansari, I., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.073 · Cited by 30
Metadata
- Authors
- Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N., & Jarlier, V.
- Affiliations
- Johnson & Johnson (United Kingdom) (GB)
- Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, 2340 Beerse, Belgium.
- Corresponding author
- Andries, Koen
- Lounis, Nacer
- Venue
- Science
- Published
- 2005-01-14
- Volume
- 307
- Issue
- 5707
- Pages
- 223-227
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2158658436
- Cited by
- 2,191
- References
- 13
- Citations by year
- 2026: 63 · 2025: 98 · 2024: 103 · 2023: 106 · 2022: 111 · 2021: 98 · 2020: 136 · 2019: 141 · 2018: 102 · 2017: 124 · 2016: 120 · 2015: 129 · 2014: 140 · 2013: 106 · 2012: 102
- FWCI
- 27.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- diarylquinolines, Mycobacterium tuberculosis, tuberculosis drug resistance, ATP synthase inhibition, proton pump, bactericidal activity, combination therapy, isoniazid
- MeSH terms
- Amino Acid Sequence, Animals, Antitubercular Agents, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Drug Therapy, Combination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
